NEW YORK, Nov. 09, 2016 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased shares of ProNAi Therapeutics, Inc. (“ProNAi”) (NASDAQ:DNAI) between July 15, 2015 and June 6, 2016 (the “Class Period”). You are hereby notified that a securities class action lawsuit has been commenced in the USDC for the Southern District of New York. To get more information go to:
http://www.zlk.com/pslra/pronai-therapeutics-inc
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that, throughout the Class Period, ProNAi made materially false and misleading statements about the potential and efficacy of its drug product candidate PNT2258 in the company’s public filings, which caused ProNAi’s stock price to be artificially inflated throughout the Class Period, thus harming investors.
On June 6, 2016, ProNAi revealed that the Phase 2 clinical trials of PNT2258 failed to produce sufficient efficacy results to justify continued clinical development of the drug and, thus, ProNAi was suspending clinical development of PNT2258. Following this news, shares of ProNAi fell more than 67 percent.
If you suffered a loss in ProNAi you have until January 9, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com


DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Washington Post Publisher Will Lewis Steps Down After Layoffs
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 



